Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARA SHELBY FRIEDMAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1649318569
CMS profile
979795
Location
ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$169.09

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $169.09 11

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie, Inc. $49.48 3
Merck Sharp & Dohme Corporation $37.82 3
Minerva Surgical, Inc $20.17 1
Astellas Pharma US Inc $20.05 1
Allergan Inc. $16.14 1
Bayer HealthCare Pharmaceuticals Inc. $14.63 1
PFIZER INC. $10.80 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARA SHELBY FRIEDMAN

NPI 1649318569 · CMS profile ID 979795

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649318569?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649318569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649318569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1649318569?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $169.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $14.6311/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628481903 CMS
Merck Sharp & Dohme Corporation $13.7110/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695830461 CMS
PFIZER INC. $10.8010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673198693 CMS
Merck Sharp & Dohme Corporation $12.5109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695784175 CMS
Allergan Inc. $16.1409/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670372263 CMS
AbbVie, Inc. $18.9708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647768191 CMS
Merck Sharp & Dohme Corporation $11.6007/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695727009 CMS
AbbVie, Inc. $17.8507/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647768189 CMS
Astellas Pharma US Inc $20.0504/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655565329 CMS
Minerva Surgical, Inc $20.1702/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705667547 CMS
AbbVie, Inc. $12.6602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647768181 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169.09 11
PY2023 $1,724.29 6
PY2024 $3,024.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,296,266.41 159
PY2024 Principal investigator $1,078,411.75 127
PY2023 Principal investigator $776,040.20 596
PY2022 Principal investigator $318,257.95 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $1,043.58 12/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963496707
Principal investigator 1 Bavarian Nordic A/S $3,218.40 12/21/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971477
Principal investigator 1 PFIZER INC. $1,020.60 12/21/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949770263
Principal investigator 1 PFIZER INC. $1,905.39 12/17/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769537
Principal investigator 1 PFIZER INC. $15,243.12 12/16/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769535
Principal investigator 1 Bavarian Nordic A/S $421.20 12/14/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971449
Principal investigator 1 PFIZER INC. $43,823.97 12/10/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769459
Principal investigator 1 Bavarian Nordic A/S $3,191.40 12/06/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971419
Principal investigator 1 PFIZER INC. $11,432.34 12/03/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769461
Principal investigator 1 Bavarian Nordic A/S $12,562.20 12/01/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971407
Principal investigator 1 PFIZER INC. $37.26 11/28/2022 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761135
Principal investigator 1 ModernaTX, Inc. $376.68 11/25/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554443
Principal investigator 1 PFIZER INC. $18.63 11/21/2022 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761133
Principal investigator 1 ModernaTX, Inc. $6,135.00 11/16/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 963554439
Principal investigator 1 Bavarian Nordic A/S $3,323.70 11/15/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971455
Principal investigator 1 PFIZER INC. $18,134.00 11/09/2022 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949782717
Principal investigator 1 Bavarian Nordic A/S $1,908.00 11/08/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971437
Principal investigator 1 PFIZER INC. $8,500.00 11/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949782683
Principal investigator 1 Bavarian Nordic A/S $4,369.50 11/02/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971413
Principal investigator 1 ModernaTX, Inc. $7,335.90 11/02/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554441
Principal investigator 1 ModernaTX, Inc. $19,000.00 10/28/2022 Non-covered Recipient Entity
MedPharmics LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 963493609
Principal investigator 1 Bavarian Nordic A/S $3,929.80 10/26/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971489
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/26/2022 Non-covered Recipient Entity
MedPharmics LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 963493613
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/26/2022 Non-covered Recipient Entity
MedPharmics LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 963493619
Principal investigator 1 PFIZER INC. $55.89 10/25/2022 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949762367
Principal investigator 1 GlaxoSmithKline, LLC. $18,350.00 10/21/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 944055039
Principal investigator 1 Bavarian Nordic A/S $2,461.50 10/18/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971465
Principal investigator 1 Bavarian Nordic A/S $862.20 10/12/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971443
Principal investigator 1 Bavarian Nordic A/S $14,268.00 10/07/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971425
Principal investigator 1 ModernaTX, Inc. $2,976.35 10/05/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554433
Principal investigator 1 Bavarian Nordic A/S $6,929.10 09/28/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971495
Principal investigator 1 PFIZER INC. $14,500.00 09/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949798747
Principal investigator 1 Bavarian Nordic A/S $12,981.80 09/20/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971472
Principal investigator 1 Bavarian Nordic A/S $16,500.00 09/15/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971501
Principal investigator 1 Bavarian Nordic A/S $1,500.00 09/15/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971513
Principal investigator 1 ModernaTX, Inc. $3,943.23 09/14/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554373
Principal investigator 1 Bavarian Nordic A/S $1,908.00 09/09/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971507
Principal investigator 1 Bavarian Nordic A/S $7,844.00 09/07/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971431
Principal investigator 1 Bavarian Nordic A/S $1,908.00 08/22/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971483
Principal investigator 1 Bavarian Nordic A/S $1,908.00 08/17/2022 Non-covered Recipient Entity
Med Pharmics, LLC
NCT05238025 No dispute reported 06/30/2026 906971459
Principal investigator 1 ModernaTX, Inc. $12,801.03 08/12/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554379
Principal investigator 1 ModernaTX, Inc. $11,630.18 07/13/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554377
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/03/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554367
Principal investigator 1 ModernaTX, Inc. $1,750.00 06/03/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554369
Principal investigator 1 ModernaTX, Inc. $3,750.00 04/27/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554371
Principal investigator 1 ModernaTX, Inc. $7,500.00 01/28/2022 Non-covered Recipient Entity
MedPharmics, LLC. - Albuquerque - Platinum - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963554375